Europe Expansion CE Mark enables commercial sales in Europe; target European hospitals and distributors seeking advanced LVAD solutions and remote monitoring; position ReliantHeart as a next-generation, compact LVAD provider with ongoing service capabilities.

Remote Monitoring Continuous wireless monitoring via the Conquest Controller offers a service differentiator; frame as a remote patient management offering, enabling reduced clinic visits and data-driven care; pursue service contracts, telemetry analytics, and predictive maintenance partnerships.

Compact Advantage Smallest and lightest LVAD at 84 grams, implantable above the diaphragm; appeal to surgeons seeking minimal invasiveness and improved patient quality of life; target centers of excellence and institutions evaluating next-generation devices.

Differentiated Tech Unique direct flow measurement and cellular remote monitoring differentiate ReliantHeart from competitors; opportunities for co-development, clinical trials, and data partnerships; attractive for grant-funded innovation programs.

Upgrade Path Ongoing R&D toward fully implantable devices suggests upgrade trajectories for existing customers; explore cross-sell opportunities to hospitals planning device modernization and align with new product introductions and funding opportunities.